NCT05239780

Invasive Decoding and Stimulation of Altered Reward Computations in Depression Patients

Recruiting now NA Last updated 25 September 2025

What this trial tests

NA trial testing Brain stimulation in Major Depressive Disorder in 10 participants. Currently enrolling.

Timeline

6 October 2021

Primary endpoint
31 August 2027

31 August 2027

Quick facts

Lead sponsor	Icahn School of Medicine at Mount Sinai
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	6 October 2021
Primary completion	31 August 2027
Estimated completion	31 August 2027
Sites	1 location across United States

Drugs / interventions tested

• Brain stimulation

Conditions studied

• Major Depressive Disorder — all drugs for Major Depressive Disorder →

Sponsor

Icahn School of Medicine at Mount Sinai

Who can join

Adults 18 to 80, any sex, with Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Novel invasive neurostimulation stimulation strategies through neurosurgical interventions are emerging as a promising therapeutical strategy for major depressive disorder. These have been applied mostly to the anterior cingulate cortex, but other limbic brain regions have shown promise as anatomical targets for new neurostimulation strategies. The researchers seek to study neural activity in limbic brain areas implicated in decision behavior and mood regulation to identify novel targets for treatment through electrical stimulation. To do this, the study team will record local field potentials (LFPs) from the orbitofrontal cortex, hippocampus and amygdala of epilepsy participants undergoing invasive monitoring (intracranial encephalography, iEEG) during choice behavior. Leveraging the high co-morbidity of depression and intractable epilepsy (33-50%), neural responses will be compared to reward across depression status to identify abnormal responses in depression. Finally, the researchers will use these as biomarkers to guide development of neurostimulation strategies for the treatment of depression.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.